On January 13th, Rainbow Coral Corp. and N3D announced a joint venture partnership to develop bio-printing solutions for drug toxicology screening. It will join the likes of Organovo and AngioMix Inc. on the growing list of companies striving to offer what will amount to the first bio-printed commercial product.
n3D’s Bio-Assembler system uses magnetic nanoparticles and magnetic drives to form cells into 3D structures. N3D’s technology shows every sign of a viable alternative to other bio-printing processes that can create 3D structures, such as BioPlotting or BioLP.
Seeing another player enter this market is an exciting development for bio-printing. It affirms the potential of the market for this kind of product, while at the same time introduce much needed competition to the bio-printing sector.